Company
Eledon Pharmaceuticals
Also known as Eledon Pharmaceuticals, Inc.
- Business model
- B2B
- Legal name
- Eledon Pharmaceuticals, Inc.
- eledon.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Eledon Pharmaceuticals is a clinical stage biotechnology company using its immunology expertise to develop therapies to protect transplanted organs and reduce the risk of organ rejection, as well as to treat autoimmune and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS).
Funding snapshot
- Total raised
- $227MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $50M2024-05-09
Funding rounds
- Round, 2024
- $50M2024-05-09, SEC form D sold, 24 investors
- Round, 2023
- $35M2023-05-05, SEC form D sold, 38 investors
- Round, 2020
- $108M2020-09-15, SEC form D sold, 35 investors
- Round, 2020
- $862K2020-01-14, SEC form D sold, 10 investors
- Round, 2019
- $862K2019-05-02, SEC form D sold, 10 investors
- Round, 2013
- $20M2013-05-13, SEC form D sold, 19 investors
- Round, 2011
- $1.9M2011-09-09, SEC form D sold, 6 investors
- Round, 2009
- $10M2009-05-06, SEC form D sold, 10 investors
Products
- Other
- tegoprubart
Loading relationship preview